Skip to main content

namzaric

Generic: memantine hydrochloride and donepezil hydrochloride

namzaric: developed by 2 companies · 1 FDA decision.

namzaric evidence translation

What we can confirm

1 FDA record

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

What is verified about namzaric, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

moderate to severe dementia of an Alzheimer's type

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (2)
CompanyPhase
AbbVie Inc. (ABBV)Approved
Adamas Pharmaceuticals Inc (ADMS)
moderate to severe dementia of an Alzheimer's type
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC is a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. ( 1 )(ABBV)FDA ↗
NDA206439Type 4 - New CombinationStandardOralCapsule, Extended Release

Frequently asked questions

Who is developing namzaric?

namzaric is being developed by AbbVie Inc., Adamas Pharmaceuticals Inc.

What is namzaric's latest FDA decision?

The most recent tracked FDA decision for namzaric is Approval for 1 INDICATIONS AND USAGE NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC is a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. ( 1 ), dated December 23, 2014.